Zosano Pharma Corporation ZSAN

$ 0.56 7.23%

Quarterly report 2022-Q1
added 12-23-2023

Zosano Pharma Corporation Balance Sheet 2011-2024 | ZSAN

Annual Balance Sheet Zosano Pharma Corporation

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-6.36 M	-33.1 M	919 K	-4.66 M	-4.96 M	-2.46 M	8.62 M	20.8 M	7.4 M	4.05 M	-
Long Term Debt	3.08 M	812 K	6.1 M	4.48 M	-	6.55 M	11.9 M	13.3 M	9.71 M	9.03 M	-
Long Term Debt Current	1.61 M	1.38 M	1.14 M	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	4.49 M	12 M	5.78 M	495 K	6.6 M	12 M	13.4 M	10.1 M	9.63 M	-
Total Current Liabilities	11.1 M	14.5 M	16.2 M	11.3 M	10.5 M	9.82 M	6.88 M	-	-	-	-
Total Liabilities	15.4 M	24.5 M	28.3 M	17.1 M	11 M	16.4 M	18.8 M	26.7 M	21.6 M	13.6 M	-
Deferred Revenue	26 K	-	-	-	-	-	-	170 K	1.12 M	3.38 M	-
Retained Earnings	-362 M	-332 M	-299 M	-261 M	-226 M	-197 M	-167 M	-138 M	-124 M	-119 M	-
Total Assets	48.4 M	72 M	37.7 M	35.8 M	18 M	20.9 M	45.3 M	13.3 M	22.1 M	19.6 M	-
Cash and Cash Equivalents	11 M	35.3 M	6.32 M	9.14 M	11.7 M	15 M	6.65 M	1.21 M	-	-	-
Book Value	33 M	47.5 M	9.39 M	18.7 M	7.05 M	4.48 M	26.5 M	-13.4 M	477 K	6.02 M	-
Total Shareholders Equity	33 M	47.5 M	9.39 M	18.7 M	7.05 M	4.48 M	26.5 M	-13.4 M	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Zosano Pharma Corporation

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	2.66 M	-	-	-	204 K	812 K	1.42 M	888 K	812 K	-	-	-	30 K	-	-	3.6 M	-	6.69 M	8.18 M	9.63 M	11.2 M	12.5 M	12.5 M	12.5 M	12.5 M	15.3 M	15.3 M	15.3 M	15.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	-	-	12.4 M	15.4 M	16.8 M	17.8 M	22.6 M	24.5 M	25.2 M	29.2 M	31.4 M	28.3 M	28.3 M	28.3 M	28.3 M	17.1 M	17.1 M	17.1 M	17.1 M	11 M	11 M	11 M	11 M	16.4 M	16.4 M	16.4 M	16.4 M	18.8 M	18.8 M	18.8 M	18.8 M	26.7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	26 K	47 K	226 K	47 K	-	-	-	-	-	-	-	-	-	-	62 K	-	-	-	-	-	-	-	-	-	-	-	-	68 K	170 K	170 K	170 K	170 K	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-396 M	-362 M	-355 M	-346 M	-340 M	-332 M	-324 M	-315 M	-308 M	-299 M	-299 M	-299 M	-299 M	-261 M	-261 M	-261 M	-261 M	-226 M	-226 M	-226 M	-226 M	-197 M	-197 M	-197 M	-197 M	-167 M	-167 M	-167 M	-167 M	-138 M	-138 M	-138 M	-138 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	-	-	-	26.4 M	48.4 M	55 M	60.8 M	65.7 M	72 M	80.5 M	47.7 M	55.3 M	37.7 M	37.7 M	37.7 M	37.7 M	35.8 M	35.8 M	35.8 M	35.8 M	18 M	18 M	18 M	18 M	20.9 M	20.9 M	20.9 M	20.9 M	45.3 M	45.3 M	45.3 M	45.3 M	13.3 M	13.3 M	13.3 M	13.3 M	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	-	-	13.5 M	11 M	17.1 M	22.1 M	26.9 M	35.3 M	35.3 M	35.3 M	35.3 M	6.32 M	6.32 M	6.32 M	6.32 M	9.14 M	9.14 M	9.14 M	9.14 M	11.7 M	11.7 M	11.7 M	11.7 M	15 M	15 M	15 M	15 M	6.65 M	6.65 M	6.65 M	6.65 M	1.21 M	1.21 M	1.21 M	1.21 M	5.91 M	-	-	-	-	-	-	-	-	-	-	-
Book Value	-	-	-	14.1 M	33 M	38.2 M	43.1 M	43.2 M	47.5 M	55.2 M	18.5 M	24 M	9.39 M	9.39 M	9.39 M	9.39 M	18.7 M	18.7 M	18.7 M	18.7 M	7.05 M	7.05 M	7.05 M	7.05 M	4.48 M	4.48 M	4.48 M	4.48 M	26.5 M	26.5 M	26.5 M	26.5 M	-13.4 M	13.3 M	13.3 M	13.3 M	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	14.1 M	33 M	38.2 M	43.1 M	43.2 M	47.5 M	55.2 M	47.5 M	24 M	9.39 M	10.4 M	9.39 M	9.39 M	18.7 M	18.7 M	18.7 M	18.7 M	7.05 M	7.05 M	7.05 M	7.05 M	4.48 M	4.48 M	4.48 M	4.48 M	26.5 M	26.5 M	26.5 M	26.5 M	-13.4 M	-13.4 M	-13.4 M	-13.4 M	477 K	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency